Atenolol
Brand names: Tenormin
Atenolol is a relatively cardioselective beta-blocker used for hypertension, angina and certain arrhythmias, and after myocardial infarction.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively blocks beta-1 adrenoceptors in the heart, reducing heart rate, myocardial contractility and conduction velocity, thereby lowering cardiac workload and blood pressure.
Prescribing in practice
- Do not stop abruptly, as sudden withdrawal can precipitate rebound angina, arrhythmia or myocardial infarction, so taper when discontinuing.
- It is renally excreted and accumulates in renal impairment, so dose reduction is needed as function declines.
- Use caution in asthma, peripheral arterial disease and with other rate-limiting drugs, and be aware it may mask signs of hypoglycaemia in diabetes.
Monitoring
Monitor heart rate and blood pressure, and assess renal function as it influences dosing and accumulation.
Counselling the patient
- Do not stop the medicine suddenly without medical advice.
- Report marked dizziness, breathlessness, wheeze or a very slow pulse.
- Be aware it may blunt the usual warning symptoms of low blood sugar if you have diabetes.
Evidence & guidelines
Beta-blockade after myocardial infarction reduces mortality, and NICE positions atenolol within the management of hypertension, angina and arrhythmia.
Reference: NICE NG133 (Hypertension in adults, 2019 updated 2023); NICE NG185 (ACS, 2020); ESC/ESH Hypertension Guidelines (2023); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines